{'url': 'https://www.cancer.gov/news-events/cancer-currents-blog/2023/immunotherapy-endometrial-cancer-pembrolizumab-dostarlimab', 'method': 'GET', 'status': 200, 'response_url': 'https://www.cancer.gov/news-events/cancer-currents-blog/2023/immunotherapy-endometrial-cancer-pembrolizumab-dostarlimab', 'timestamp': 1711314714.7208314}